Cyclophosphamide
Pediatric Lymphoma
Actuate Therapeutics Inc.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Pediatric Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
axp107-11 University of Virginia | Phase 2 | CCC |
iopofosine (¹³¹I) Cellectar Biosciences, Inc. | Phase 1 | CC |
Irinotecan Actuate Therapeutics Inc. | Phase 1 | CC |
Hycamtin Actuate Therapeutics Inc. | Phase 1 | CC |
Decitabine Children's Hospital Medical Center, Cincinnati | Early Phase 1 | CC |
Pembrolizumab Children's Hospital Medical Center, Cincinnati | Early Phase 1 | CC |
ELRAGLUSIB Actuate Therapeutics Inc. | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →